{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:20:07Z","timestamp":1790014807770,"version":"4.0.1"},"reference-count":34,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"abstract":"<jats:sec id=\"ab-poi260049-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>In February 2025, Australia introduced maternal vaccination with bivalent respiratory syncytial virus prefusion F protein\u2013based vaccine (RSVpreF) in the National Immunization Program for pregnant individuals from 28 weeks\u2019 gestation as the primary, year-round strategy to prevent RSV disease in infants 6 months of age or younger.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-poi260049-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate effectiveness of RSVpreF vaccination during pregnancy against infant RSV hospitalization in Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-poi260049-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This retrospective case-control study with a test-negative design was conducted in 9 hospitals across Australia with year-round respiratory testing for acute respiratory illness (ARI) among infants born from 28 weeks\u2019 gestation and hospitalized with ARI at 6 months of age or younger, March 1, 2025, through February 28, 2026. Data were analyzed March 2026 through May 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-poi260049-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Maternal RSVpreF vaccination administered from 28 weeks\u2019 gestation and 14 days or more before delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-poi260049-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Maternal RSVpreF effectiveness was evaluated against hospitalization for RSV lower respiratory tract disease (RSV-LRTD, primary objective), severe RSV-LRTD, and RSV-ARI. Logistic regression with confounder adjustment was used to calculate vaccine effectiveness (VE) as (1\u2009\u2212\u2009adjusted odds ratio)\u2009\u00d7\u2009100%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-poi260049-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1012 infants hospitalized with ARI, 655 had LRTD, with 114 of 386 case infants (30%) and 171 of 269 control infants (64%) born to RSVpreF-vaccinated mothers (median [IQR] gestational age at vaccination, 31 weeks [29-33]). Median (IQR) maternal age at delivery was 32 years (29-35). Median (IQR) age of infants hospitalized for LRTD was 52 days (30-89); 495 of 655 (76%) were aged 3 months or younger. VE against RSV-LRTD hospitalization was 77.8% (95% CI, 66.4%-85.3%) among infants from birth through 6 months of age, 80.2% (95% CI, 71.1%-86.5%) among infants from birth through 3 months of age, 86.3% (95% CI, 79.0%-91.1%) among infants from birth through 2 months of age, and 68.2% (95% CI, 42.2%-82.5%) among infants older than 2 months through 4 months of age. Comparable VE among infants aged 6 months or younger was observed for severe RSV-LRTD (80.4%; 95% CI, 54.4%-91.6%) and RSV-ARI (80.8%; 95% CI, 70.4%-87.6%) hospitalization, with similar age-specific trends. VE was consistent across stratifications by gestational age at vaccination, vaccination to delivery time interval, and proximal administration with other vaccines during pregnancy. Descriptively, among all infants hospitalized with ARI, 161 of 499 (32%) born to RSVpreF-unvaccinated mothers had severe LRTD, while 87 of 513 (17%) born to RSVpreF-vaccinated mothers had severe LRTD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-poi260049-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Findings in this case-control study demonstrate high year-round effectiveness of RSVpreF vaccination against RSV-associated hospitalization in infants 6 months of age or younger in the first year following introduction in Australia, with the highest VE observed in the earliest age intervals. Future analyses with larger sample sizes will evaluate VE among additional subgroups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamapediatrics.2026.3391","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:30:24Z","timestamp":1786980624000},"source":"Crossref","is-referenced-by-count":4,"title":["Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants"],"prefix":"10.1001","author":[{"given":"Ushma","family":"Wadia","sequence":"first","affiliation":[{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia"},{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital, Nedlands, Western Australia, Australia"},{"name":"Department of General Paediatrics, Fiona Stanley Hospital, Murdoch, Western Australia, Australia"},{"name":"School of Medicine, The University of Western Australia, Nedlands, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline M.","family":"Ong","sequence":"additional","affiliation":[{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah N.","family":"Cox","sequence":"additional","affiliation":[{"name":"Pfizer, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huong","family":"Le","sequence":"additional","affiliation":[{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia"},{"name":"School of Medicine, The University of Western Australia, Nedlands, Western Australia, Australia"},{"name":"School of Population Health, Curtin University, Bentley, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Foo","sequence":"additional","affiliation":[{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia"},{"name":"Faculty of Health Sciences, Curtin University, Bentley, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"Wolf Mankiewicz","sequence":"additional","affiliation":[{"name":"Pfizer, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Carr","sequence":"additional","affiliation":[{"name":"Monash Children\u2019s Hospital, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen S.","family":"Marshall","sequence":"additional","affiliation":[{"name":"College of Health, Adelaide University, North Adelaide, South Australia, Australia"},{"name":"Vaccinology and Immunology Research Trials Unit, Women\u2019s and Children\u2019s Hospital Network, North Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia E.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Health Queensland, Brisbane, Queensland, Australia"},{"name":"School of Clinical Medicine, University of Queensland, Herston, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Britton","sequence":"additional","affiliation":[{"name":"The Children\u2019s Hospital at Westmead, Sydney, New South Wales, Australia"},{"name":"Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"McMullan","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Sydney Children\u2019s Hospital, Randwick, New South Wales, Australia"},{"name":"School of Clinical Medicine, The University of New South Wales, Kensington, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Tan","sequence":"additional","affiliation":[{"name":"Pfizer, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirke","family":"Wiid","sequence":"additional","affiliation":[{"name":"Pfizer Australia, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shidan","family":"Tosif","sequence":"additional","affiliation":[{"name":"Infection and Immunity, Murdoch Children\u2019s Research Institute, Parkville, Victoria, Australia"},{"name":"Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia"},{"name":"Department of General Medicine, The Royal Children\u2019s Hospital, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Yu","family":"Hung","sequence":"additional","affiliation":[{"name":"Royal Darwin Hospital, Menzies School of Health Research, Darwin, Northern Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah C.","family":"Moore","sequence":"additional","affiliation":[{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia"},{"name":"School of Medicine, The University of Western Australia, Nedlands, Western Australia, Australia"},{"name":"School of Population Health, Curtin University, Bentley, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla","family":"Hayford","sequence":"additional","affiliation":[{"name":"Pfizer, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Can\u00e9","sequence":"additional","affiliation":[{"name":"Pfizer, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshayne B.","family":"Fell","sequence":"additional","affiliation":[{"name":"Pfizer, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Atwell","sequence":"additional","affiliation":[{"name":"Pfizer, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Richmond","sequence":"additional","affiliation":[{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia"},{"name":"School of Medicine, The University of Western Australia, Nedlands, Western Australia, Australia"},{"name":"Departments of Immunology and General Paediatrics, Perth Children\u2019s Hospital, Nedlands, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"STREETON Study Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Finucane","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kets","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Gibson","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Ghosh","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kent","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Vichnin","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillian","family":"Hunter","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Au","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Shine","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Harlow","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Chung","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Henry","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredieth","family":"Krieg","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Oldfield","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Martin","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arockia","family":"Sugantharaj","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"D'Angelo","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suja","family":"Matthew","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeevaki","family":"Kuruppu","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Dougherty","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Doran","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cook","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Wong","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Carey","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Meredith","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Martin","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"McMinn","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Harris","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Fernando","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Binks","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Francis","sequence":"additional","affiliation":[{"name":"for the STREETON Study Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"10340","key":"poi260049r1","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"issue":"10098","key":"poi260049r2","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study.","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"poi260049r3","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(22)00291-2","article-title":"Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.","volume":"23","author":"Mazur","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"poi260049r4","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children.","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"poi260049r5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jpids\/piz011","article-title":"Respiratory syncytial virus-associated outpatient visits among children younger than 24 months.","volume":"8","author":"Lively","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"2","key":"poi260049r9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.18773\/austprescr.2025.018","article-title":"RSV: an update on prevention and management.","volume":"48","author":"Foley","year":"2025","journal-title":"Aust Prescr"},{"issue":"9","key":"poi260049r10","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S1473-3099(25)00156-2","article-title":"Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study.","volume":"25","author":"P\u00e9rez Marc","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"poi260049r11","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1097\/INF.0000000000004878","article-title":"Maternal immunization with RSVpreF vaccine: effectiveness in preventing respiratory syncytial virus-associated hospitalizations in infants under 6 months in Argentina: multicenter case-control study.","volume":"44","author":"Gentile","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"poi260049r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101296","article-title":"Impact and effectiveness of RSV maternal immunization on infant hospitalizations in Buenos Aires: a hospital-based, multicentre, retrospective surveillance cohort study.","volume":"52","author":"Razzini","year":"2025","journal-title":"Lancet Reg Health Am"},{"issue":"4","key":"poi260049r13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1473-3099(25)00624-3","article-title":"Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case-control study and cohort analysis.","volume":"26","author":"McLachlan","year":"2026","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"poi260049r14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2352-4642(25)00155-5","article-title":"Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study.","volume":"9","author":"Williams","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"poi260049r15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf695.1622","article-title":"P-1435. effectiveness of RSV immunization among infants in their first RSV season in the United States, 2023-2024 and 2024-2025 seasons.","volume":"13","author":"Payne","year":"2026","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"poi260049r16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/jamapediatrics.2025.5778","article-title":"Effectiveness and impact of maternal RSV immunization and nirsevimab on medically attended RSV in US children.","volume":"180","author":"Moline","year":"2026","journal-title":"JAMA Pediatr"},{"issue":"17","key":"poi260049r19","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.vaccine.2013.02.053","article-title":"The test-negative design for estimating influenza vaccine effectiveness.","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"poi260049r20","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1093\/ije\/dyw124","article-title":"Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies.","volume":"45","author":"Lipsitch","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"8","key":"poi260049r21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"11","key":"poi260049r22","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/aje\/kwaa084","article-title":"Temporal confounding in the test-negative design.","volume":"189","author":"Dean","year":"2020","journal-title":"Am J Epidemiol"},{"issue":"2","key":"poi260049r23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2204399","article-title":"Maternal vaccination and risk of hospitalization for COVID-19 among infants.","volume":"387","author":"Halasa","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"poi260049r24","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1093\/infdis\/jiad539","article-title":"Effectiveness of influenza vaccination during pregnancy against laboratory-confirmed seasonal influenza among infants under 6 months of age in Ontario, Canada.","volume":"230","author":"Fell","year":"2024","journal-title":"J Infect Dis"},{"issue":"3","key":"poi260049r25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/EDE.0000000000001470","article-title":"Estimands and estimation of COVID-19 vaccine effectiveness under the test-negative design: connections to causal inference.","volume":"33","author":"Schnitzer","year":"2022","journal-title":"Epidemiology"},{"issue":"16","key":"poi260049r26","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants.","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"poi260049r27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","article-title":"Efficacy, safety, and immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial.","volume":"145","author":"Sim\u00f5es","year":"2025","journal-title":"Obstet Gynecol"},{"issue":"6","key":"poi260049r29","doi-asserted-by":"publisher","first-page":"554.e1","DOI":"10.1016\/j.ajog.2024.10.053","article-title":"Enhanced placental antibody transfer efficiency with longer interval between maternal respiratory syncytial virus vaccination and birth.","volume":"232","author":"Jasset","year":"2025","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"poi260049r30","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jama.2025.23452","article-title":"Interim safety of RSVpreF vaccination during pregnancy.","volume":"335","author":"Michnick","year":"2026","journal-title":"JAMA"},{"issue":"1","key":"poi260049r31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/AOG.0000000000006130","article-title":"Maternal respiratory syncytial virus vaccination and preterm birth: a Utah statewide retrospective cohort study.","volume":"147","author":"Solsman","year":"2026","journal-title":"Obstet Gynecol"},{"issue":"1","key":"poi260049r32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/AOG.0000000000006121","article-title":"Maternal and neonatal outcomes after respiratory syncytial virus prefusion F protein vaccination during pregnancy: analysis from the 2024-2025 immunization campaign in France.","volume":"147","author":"Gabet","year":"2026","journal-title":"Obstet Gynecol"},{"issue":"5","key":"poi260049r33","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.ajog.2025.04.067","article-title":"Investigation of maternal outcomes following respiratory syncytial virus vaccination in the third trimester: insights from a real-world United States electronic health records database.","volume":"233","author":"Hsieh","year":"2025","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"poi260049r34","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1093\/infdis\/jiab505","article-title":"Safety and immunogenicity of a respiratory syncytial virus prefusion F vaccine when coadministered with a tetanus, diphtheria, and acellular pertussis vaccine.","volume":"225","author":"Peterson","year":"2022","journal-title":"J Infect Dis"},{"key":"poi260049r6","unstructured":"National Centre for Immunisation Research and Surveillance (NCIRS). Respiratory syncytial virus (RSV): frequently asked questions (FAQs). Accessed May 7, 2025, 2025. https:\/\/ncirs.org.au\/ncirs-fact-sheets-faqs-and-other-resources\/respiratory-syncytial-virus-rsv-frequently-asked"},{"key":"poi260049r7","unstructured":"Australian Register of Therapeutic Goods (ARTG). ABRYSVO recombinant respiratory syncytial virus pre-fusion F protein 120 microgram\/0.5 mL bivalent vaccine powder for injection vial + diluent syringe (406624). Accessed May 7, 2025. https:\/\/www.tga.gov.au\/resources\/artg\/406624"},{"key":"poi260049r8","unstructured":"Australian Immunisation Handbook, Australian Centre for Disease Control. Respiratory syncytial virus (RSV). Accessed March 17, 2026. https:\/\/immunisationhandbook.health.gov.au\/contents\/vaccine-preventable-diseases\/respiratory-syncytial-virus-rsv"},{"key":"poi260049r17","unstructured":"STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON). ClinicalTrials.gov. Accessed March 17, 2026. https:\/\/clinicaltrials.gov\/study\/NCT07122661"},{"key":"poi260049r18","unstructured":"STudy of Real world vaccinE Effectiveness of maTernal RSVpreF vaccinatiON against respiratory syncytial virus (RSV) in hospitalised infants in Australia (STREETON). HMA-EMA Catalogues of Real-World Data Sources and Studies. Accessed March 17, 2026. https:\/\/catalogues.ema.europa.eu\/node\/4499\/administrative-details"},{"key":"poi260049r28","unstructured":"Joint Committee on Vaccination and Immunisation (JCVI). RSV sub-committee of the Joint Committee on Vaccination and Immunisation. Draft minutes of the meeting held on September 22, 2025. Accessed May 7, 2025. https:\/\/www.gov.uk\/government\/groups\/joint-committee-on-vaccination-and-immunisation#meetings-agendas-and-minutes"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2852944\/jamapediatrics_wadia_2026_oi_260049_1786975204.44603.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:30:26Z","timestamp":1786980626000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2852944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2026.3391","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}